CNR Institutional Research Information System

SANTORO, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.321
NA - Nord America 1.742
EU - Europa 599
SA - Sud America 487
AF - Africa 43
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 5
Totale 5.206
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.648
SG - Singapore 989
CN - Cina 533
BR - Brasile 384
HK - Hong Kong 266
VN - Vietnam 230
IT - Italia 190
FR - Francia 127
NL - Olanda 87
KR - Corea 79
BD - Bangladesh 56
CA - Canada 47
DE - Germania 45
AR - Argentina 42
JP - Giappone 41
GB - Regno Unito 35
FI - Finlandia 34
IN - India 24
CO - Colombia 22
MX - Messico 21
EC - Ecuador 20
ID - Indonesia 14
IL - Israele 12
ZA - Sudafrica 12
ES - Italia 11
UA - Ucraina 11
SC - Seychelles 10
IQ - Iraq 9
SE - Svezia 8
VE - Venezuela 8
AT - Austria 7
JM - Giamaica 7
MY - Malesia 7
PH - Filippine 7
TR - Turchia 7
KZ - Kazakistan 6
PL - Polonia 6
RU - Federazione Russa 6
OM - Oman 5
PK - Pakistan 5
SA - Arabia Saudita 5
TN - Tunisia 5
UZ - Uzbekistan 5
CR - Costa Rica 4
DZ - Algeria 4
IE - Irlanda 4
LB - Libano 4
MA - Marocco 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
BG - Bulgaria 3
CL - Cile 3
DO - Repubblica Dominicana 3
EE - Estonia 3
HN - Honduras 3
KE - Kenya 3
LT - Lituania 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BN - Brunei Darussalam 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
GT - Guatemala 2
HU - Ungheria 2
LV - Lettonia 2
NP - Nepal 2
PE - Perù 2
TH - Thailandia 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CY - Cipro 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
GU - Guam 1
HR - Croazia 1
IR - Iran 1
IS - Islanda 1
JO - Giordania 1
LK - Sri Lanka 1
LY - Libia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
RO - Romania 1
SR - Suriname 1
SV - El Salvador 1
UY - Uruguay 1
Totale 5.197
Salva come PNG Salva come JPEG
Città #
Singapore 567
Santa Clara 557
Hong Kong 262
Hefei 189
San Jose 149
Ashburn 124
Beijing 106
Lauterbourg 105
Seoul 79
Ho Chi Minh City 77
Hanoi 58
Los Angeles 54
New York 36
Helsinki 34
Dallas 29
São Paulo 28
Tokyo 26
Frankfurt am Main 21
Buffalo 19
Milan 19
Rome 19
Chicago 17
Brasília 14
Naples 14
Atlanta 13
Belo Horizonte 13
Da Nang 13
Rio de Janeiro 13
Minamishinagawa 12
Montreal 11
Haiphong 9
Philadelphia 9
Phoenix 9
Bari 8
Bengaluru 8
Düsseldorf 8
Falkenstein 8
Johannesburg 8
Orem 8
Bogotá 7
Dhaka 7
Dublin 7
Guayaquil 7
Portsmouth 7
Washington 7
Brooklyn 6
Council Bluffs 6
Denver 6
Houston 6
Madrid 6
Newark 6
Ninh Bình 6
Quận Bình Thạnh 6
Stockholm 6
Toronto 6
Baghdad 5
Boardman 5
Buenos Aires 5
Campinas 5
Jacksonville 5
Manchester 5
Mexico City 5
Quito 5
San Francisco 5
Uberaba 5
Uberlândia 5
Verona 5
Biên Hòa 4
Cleveland 4
El Paso 4
Elk Grove Village 4
Florence 4
Greenville 4
Hangzhou 4
Kingston 4
Medellín 4
Medford 4
Palermo 4
Paris 4
Pittsburgh 4
Richmond 4
Santo André 4
Shanghai 4
Sumaré 4
Tashkent 4
Turin 4
Warsaw 4
Acalanes Ridge 3
Agawam 3
Arujá 3
Blumenau 3
Bologna 3
Boston 3
Calgary 3
Camden 3
Cary 3
Catania 3
Charlotte 3
Chennai 3
Córdoba 3
Totale 3.034
Salva come PNG Salva come JPEG
Nome #
The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. 93
ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases. 90
Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas. 89
Indoleamine 2,3-Dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment 89
Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. 85
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. 80
The b-catenin Axis Integrates Multiple Signals Downstream From RET/PTC and Leads to Cell Proliferation. 75
Attacking cancer with molecularly targeted agents Editorial overview 70
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. 69
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma 67
UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. 66
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. 65
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 64
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. 60
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. 60
Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice 59
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. 57
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. 57
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). 56
Tumour Suppressor Role of the CL2/DRO1/CCDC80 Gene in Thyroid Carcinogenesis. 56
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. 55
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. 55
Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. 55
XB130 mediates cancer cell proliferation and survival through multiple signaling events downstream of Akt. 54
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. 53
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies 53
Genetics: The genomic landscape of papillary thyroid carcinoma 52
The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane 52
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. 52
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 52
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. 51
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. 51
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. 51
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma 50
Identification of novel small molecule inhibitors of oncogenic RET kinase 50
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation 50
Thyroid cell transformation requires the expression of the HMGA1 proteins. 49
Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia 49
RET/PTC activation in human thyroid carcinomas 49
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. 49
The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. 48
XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. 48
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. 47
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. 47
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. 47
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 47
Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma 47
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. 47
Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines 46
Ret-mediated mitogenesis requires Src kinase activity 45
Oncogenic rearrangements driving ionizing radiation-associated human cancer 45
Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. 45
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. 44
Receptor tyrosine kinase inhibitors in thyroid cancer. 44
A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. 43
RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. 43
A new mechanism of BRAF activation in human thyroid papillary carcinomas. 42
BRAF is a therapeutic target in aggressive thyroid carcinoma. 42
Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. 42
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. 40
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. 40
The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway. 39
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. 38
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. 38
OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. 38
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. 38
Central role of RET in thyroid cancer 38
Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. 38
Low frequency of p53 mutations in human thyroid tumors: p53 and Ras mutation in two aut of fifty-six thyroid carcinomas 37
Overexpression of the HIP gene coding for a Heparin/Heparan Sulfate-binding protein in human thyroid carcinomas 37
Rat protein tyrosine phosphatase eta physically interacts with the PDZ domains of syntenin. 37
Pros and cons of cellular studies in developing new drugs for thyroid cancers. 36
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. 36
Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation. 36
SOD3 Decreases Ischemic Injury Derived Apoptosis through Phosphorylation of Erk1/2, Akt, and FoxO3a. 36
Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. 35
Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice. 35
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas 34
Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival 34
BAY 43-9006 inhibition of oncogenic RET mutants. 34
RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. 33
Minireview: RET: normal and abnormal functions 33
The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive 33
Mast cells have a protumorigenic role in human thyroid cancer. 33
RET/PTC oncogene activation is an early event in thyroid carcinogenesis 32
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes 32
Different mutations of the RET gene cause different human tumoral diseases 32
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture 31
Dysfunction of the RET receptor in human cancer. 30
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells 30
Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. 30
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential 30
RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors. 30
The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. 29
A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. 29
Glial cell line-Derived Neurotrophic Factor differentially stimulates Ret mutants associated with the Multiple Endocrine Neoplasia type 2 syndromes and Hirschsprung's disease 29
Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. 29
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. 28
Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret 28
Receptor tyrosine kinases as targets for anticancer therapeutics. 28
Totale 4.681
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.607
article - articoli 17.607
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.214
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202421 0 0 0 0 0 0 0 0 5 0 16 0
2024/20251.868 6 7 136 68 509 70 19 114 43 128 417 351
2025/20262.631 112 261 254 406 508 141 368 138 127 149 92 75
2026/2027686 159 159 368 0 0 0 0 0 0 0 0 0
Totale 5.206